Connect with us
European Gaming Congress 2024

Artificial Intelligence

Rentschler Biopharma and Leukocare extend service offering with joint U.S. site

Published

on

  • Leukocare joins Rentschler Biopharma in the U.S., facilitating integrated alliance capabilities and enhanced service for North American clients
  • Client-focused approach and integration of best-in-class formulation throughout the development process create significant value and speed time-to-market
  • Companies celebrate fourth anniversary of highly successful strategic alliance for biopharmaceutical development and formulation

LAUPHEIM, Germany and MARTINSRIED, Germany, and MILFORD, Mass., March 22, 2021 (GLOBE NEWSWIRE) — Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Leukocare AG, a German biotechnology company specialized in the field of biopharmaceutical formulation development, celebrate the fourth anniversary of their unique strategic alliance. Established in 2017 and recently expanded into the U.S., this highly successful alliance integrates best-in-class and tailored formulation development into every step of the manufacturing process and helps to efficiently address the challenges of increasingly complex biopharmaceuticals. Clients benefit from this alliance through shorter development timelines, cost savings and potentially additional patent protection, leading to a competitive edge and enhanced client satisfaction.

During these past four years, the alliance has successfully completed a large number of projects for companies around the globe. The project areas range from established monoclonal antibodies to innovative multispecific formats, as well as novel enzymes and scaffolds. They include both early- and late-stage development programs, highlighting the adaptability and flexibility of tailored services offered by the partnership. With the recent opening of Leukocare’s U.S. development labs and offices at Rentschler Biopharma’s facility in the Greater Boston area, the two companies will work together closely and seamlessly in the U.S. as well as in Europe.

Dr. Frank Mathias, CEO of Rentschler Biopharma SE, commented: “Our strategic alliance with Leukocare is a great success for our two companies and, importantly, for our clients. Formulation issues often lead to the failure of drug development projects or significant delays both in early and late clinical stage, making formulation a critical success factor. Drug development and formulation need to cooperate, and, together, our two companies can address client needs in early- or late-stage development, as well as in commercial manufacturing optimization. We are delighted that this alliance now has a solid footprint in both Europe and the U.S.”

Michael Scholl, CEO of Leukocare AG, added: “Both of our companies are highly focused on not just meeting but exceeding client expectations. Already four years ago, we recognized an increasing demand for advanced and accelerated formulation development services combined with excellent CDMO services. We are excited to expand our presence into the U.S., enabling us to work closely with Rentschler Biopharma on both sides of the Atlantic to provide optimal solutions and customized services for each joint project. We very much look forward to continuing this strong and highly fruitful partnership.”

Biopharmaceuticals are becoming increasingly complex, bringing new challenges in both biomanufacturing and formulation development. Rentschler Biopharma and Leukocare have solved many complex challenges through innovation, cutting-edge technology, and their teams’ extensive expertise. Formulation development projects within the alliance included: adjustment of existing formulations and creation of novel formulations for improving stability or extension of storage time at room temperature. Integrating formulation development know-how in downstream processing often creates additional benefits for clients, e.g., by increasing product yield. The coming together of world-class capabilities in formulation development and high-quality biomanufacturing offer best-in-class project delivery for clients along the entire biopharmaceutical value chain.

About Rentschler Biopharma SE

Advertisement

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,000 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany and Milford, MA, USA, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.
The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product’s needs.
Leukocare’s superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

www.leukocare.com

Advertisement

About the Rentschler Biopharma and Leukocare alliance

Launched in 2017, the global alliance between Rentschler Biopharma SE and Leukocare AG aims at integrating formulation development strategically into every step of biopharmaceutical value chain. Working closely with the client ensures a tailored and best-in-class approach for the client’s drug product. This innovative approach offers clients significant competitive advantages, enabling them to optimize time-to-market and exploit the full commercial potential of their products and markets.

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Xinhua Silk Road: E China’s Changzhou City unveils investment opportunities in sectors of new productive forces for global investors

Published

on

xinhua-silk-road:-e-china’s-changzhou-city-unveils-investment-opportunities-in-sectors-of-new-productive-forces-for-global-investors

BEIJING, Sept. 29, 2024 /PRNewswire/ — Changzhou City, an leading international smart manufacturing base located in east China’s Jiangsu Province, has released a bunch of investment investment opportunities to global investors in various sectors of new productive forces at the the 2024 New Energy Industry Development Conference & Invest in Changzhou Conference held in the city on September 19.

The investment opportunities covers nine areas including synthetic biology, low-altitude economy, intelligent connected new energy vehicles, solid-state batteries, hydrogen energy, third-generation semiconductors, and artificial intelligence, manifesting the confidence of Changzhou in further opening development. 
Changzhou, seated in the axis of the Yangtze River Delta, has become an important base for advanced manufacturing in China.
In recent years, thanks to intensified efforts in developing new energy industry and fostering new quality productive forces, Changzhou has expanded the added value of its industrial sector to more than two trillion yuan, with manufacturing added value accounting for about 43 percent, both ranking among the top three in Jiangsu Province.
In the Hurun China New Energy Cities 2024, a list released by the Hurun Research Institute at the conference, Changzhou ranked first among other cities in the country for three consecutive years in terms of investment attractiveness and concentration.
Changzhou has accumulated a total of 10.59 billion US dollars (nearly 74.25 billion yuan) in terms of actually utilized foreign capital since 2020. Major projects such as soft magnetism of ArcelorMittal and medical device of BIOS, a Hong Kong-based company, have been launched during the conference. 
In addition, Changzhou has released a multilingual guide for foreign nationals in Changzhou at the conference, which includes practical service items in stay and residence, work, convenient payment options, among others, turning the city into a more open and international place.
Original link: https://en.imsilkroad.com/p/342380.html
Photo – https://mma.prnewswire.com/media/2518604/Changzhou.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/xinhua-silk-road-e-chinas-changzhou-city-unveils-investment-opportunities-in-sectors-of-new-productive-forces-for-global-investors-302261868.html

Continue Reading

Artificial Intelligence

CGTN: China honors individuals with highest awards in celebration of 75th National Day

Published

on

cgtn:-china-honors-individuals-with-highest-awards-in-celebration-of-75th-national-day

BEIJING, Sept. 29, 2024 /PRNewswire/ — Huang Zongde enlisted in the Chinese People’s Liberation Army at the age of 17, beginning a nearly four-decade-long military career where his bravery, valor and devotion earned him countless awards and honors.

The heavily decorated 93-year-old received the highest state honor on Sunday when Chinese President Xi Jinping conferred him with the Medal of the Republic at a ceremony in the Great Hall of the People in Beijing.
China awarded national medals and national honorary titles to 15 individuals, including Huang, in recognition of their contribution and achievement as it celebrates the 75th anniversary of the founding of the People’s Republic of China, which falls on October 1.
Chinese heroes and role models
In addition to Huang, three others were awarded the Medal of the Republic. Wang Yongzhi, a missile and rocket expert and a pioneer of China’s manned space program, was honored posthumously. Wang Zhenyi, a medical scientist known for breakthroughs in leukemia treatment, and Li Zhensheng, an expert in wheat breeding, are also among the honorees.
The national honorary titles went to 10 people, including scientists, a border patrolman, an artist, a craftsman, educators, a health worker, an economist and an athlete.
Addressing Sunday’s awarding ceremony, President Xi, also general secretary of the Communist Party of China Central Committee and chairman of the Central Military Commission, called on the Chinese people to learn from heroes and role models to form a mighty force to build a strong China.
China is in a crucial period for building a great modern socialist country in all respects and achieving national rejuvenation through Chinese modernization, he said.
Encouraging the Chinese people to strive for extraordinary achievements at ordinary job posts, Xi urged them to contribute to resolving challenges to development and reform and safeguarding social harmony and stability.
China’s old friends and good friends
As its highest state honor for foreigners, China awarded the Friendship Medal to Dilma Rousseff, president of the New Development Bank and former Brazilian president, for her commitment to the friendship between China and Brazil, and development of relationship between China and the Community of Latin American and Caribbean States, and cooperation among BRICS countries, a group of major emerging economies.
Accepting the honor at the ceremony, Rousseff said the medal symbolizes the strong bonds between Brazil and China and pledged to continue her unremitting efforts to promote the friendship.
China’s achievements over the decades, including economic transformation, technological innovation and remarkable social development, have made it a beacon and a source of inspiration for the world, she said.
Xi lauded Rousseff as an outstanding representative of China’s old friends and good friends who have shared the same aspirations and stood together with the Chinese people over the past 75 years and vowed that China will never forget such international friends.
The Chinese people are ready to join hands with people from all over the world to safeguard world peace, promote common development and advance the building of a community with a shared future for mankind to create a better future for humanity, he said.
https://news.cgtn.com/news/2024-09-29/China-honors-individuals-with-highest-awards-ahead-of-National-Day-1xhS1SaZeZa/p.html
 

View original content:https://www.prnewswire.co.uk/news-releases/cgtn-china-honors-individuals-with-highest-awards-in-celebration-of-75th-national-day-302261867.html

Continue Reading

Artificial Intelligence

Kazakhstan Government Delegation Visited SUPCON

Published

on

kazakhstan-government-delegation-visited-supcon

HANGZHOU, China, Sept. 29, 2024 /PRNewswire/ — On September 26, a delegation from the Ministry of Digital Development, Innovations and Aerospace Industry of the Republic of Kazakhstan, led by Minister Madiyev Zhaslan, visited SUPCON. SUPCON’s Chairman and President, Mr.Cui Shan, warmly welcomed the delegation.

The Kazakhstan government representatives expressed their appreciation and recognition of SUPCON’s expertise and innovation in intelligent manufacturing, digital transformation, and industrial AI.
Madiyev Zhaslan expressed a strong interest in industrial AI technologies of SUPCON, particularly their applications in intelligent and low-carbon facilities. He looks forward to exploring extensive collaboration with SUPCON across various sectors in Kazakhstan.
Cui Shan emphasized that as a leading industrial AI company with a global presence, SUPCON will leverage its technological advantages to meet Kazakhstan’s industry development requirements and trends, injecting new momentum into the country’s industrial digitalization.
In 2023, SUPCON established a subsidiary in Kazakhstan as its Central Asia regional headquarters and set up a localized operational system. SUPCON will continue to invest in the long-term development of the Central Asia region, contributing further wisdom and strength to the industrial digital transformation in Kazakhstan and beyond.
Photo – https://mma.prnewswire.com/media/2518470/image_5022684_18905906.jpg Photo – https://mma.prnewswire.com/media/2518471/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/kazakhstan-government-delegation-visited-supcon-302261857.html

Continue Reading

Trending